Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,344.70% | 1,281.40% | 210.74% | 160.69% | 144.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,344.70% | 1,281.40% | 210.74% | 160.69% | 144.18% |
| Cost of Revenue | 3,358.41% | 2,919.86% | 218.03% | 154.13% | 113.03% |
| Gross Profit | 612.46% | 690.86% | 204.15% | 165.88% | 437.97% |
| SG&A Expenses | 21.12% | 26.29% | 291.74% | 166.67% | 27.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.82% | 63.76% | 630.07% | 301.66% | 42.98% |
| Operating Income | 2.44% | -9.64% | -56.49% | -77.09% | -20.00% |
| Income Before Tax | 17.84% | 3.25% | -23.19% | -44.30% | -25.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.40% | 30.96% | -23.19% | -44.30% | -25.55% |
| Earnings from Discontinued Operations | 3,251.85% | 2,038.69% | 2,607.02% | 3,749.05% | -230.90% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 219.83% | 219.56% | 230.55% | 221.68% | -32.75% |
| EBIT | 2.44% | -9.64% | -56.49% | -77.09% | -20.00% |
| EBITDA | 1.30% | -10.66% | -57.98% | -79.66% | -19.92% |
| EPS Basic | 220.33% | 216.10% | 225.82% | 214.10% | -27.66% |
| Normalized Basic EPS | 27.68% | 11.52% | -21.28% | -44.78% | -16.45% |
| EPS Diluted | 167.87% | 162.77% | 162.09% | 161.39% | -41.70% |
| Normalized Diluted EPS | 30.46% | 14.20% | -18.84% | -42.75% | -14.47% |
| Average Basic Shares Outstanding | 7.44% | 5.34% | 6.56% | 6.24% | 6.50% |
| Average Diluted Shares Outstanding | 8.00% | 5.99% | 7.17% | 6.87% | 10.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |